natgillin/translations-raw huggingface dataset:
Chronic continuous infusions of epoprostenol in patients with idiopathic or heritable pulmonary arterial hypertension (PAH) were studied in two prospective, open, randomised trials of 8 and 12 weeks' duration (N=25 and N=81, respectively) comparing epoprostenol plus conventional therapy to conventional therapy alone.
• Kronično stalno infundiranje epoprostenola pri bolnikih z idiopatsko ali dedno pljučno arterijsko hipertenzijo (PAH) so proučili v dveh prospektivnih, odprtih, naključnih preskušanjih, ki sta trajali osem in 12 tednov (n = 25 oz. n = 81), in primerjali epoprostenol in konvencionalno zdravljenje s konvencionalnim zdravljenjem samim.
Following all the changes in the SmPC there are several corresponding changes to the Package Leaflet After the corrections were implemented a Readability Testing was performed which was submitted and assessed during the referral procedure.
Po vnosu popravkov je bil opravljen test berljivosti, ki je bil predložen in ocenjen v napotitvenem postopku.
The MAH was asked to evaluate all other sections of the nationally approved SmPC and suggest appropriate changes in the text where divergences exist.
• Imetnik dovoljenja za promet z zdravilom je bil naprošen, da oceni vsa poglavja nacionalno odobrenih povzetkov glavnih značilnosti zdravila in predlaga ustrezne spremembe besedila, kjer obstajajo razlike.
Improvements from baseline in cardiac index (0.33 vs. -0.12 L/min/m2), stroke volume (6.01 vs. -1.32 mL/beat), arterial oxygen saturation (1.62 vs. -0.85%), mean pulmonary artery pressure (-5.39 vs.
• Izboljšanje od izhodišča za srčni indeks (0,33 v primerjavi z -0,12 l/min/m2), utripni volumen srca (6,01 v primerjavi z -1,32 ml/utrip), nasičenost kisika v arterijski krvi (1,62 v primerjavi z -0,85 %), srednji pljučni arterijski tlak (-5,39 v primerjavi z 1,45 mm Hg), srednji tlak v desnem preddvoru (-2,26
Flolan is indicated for Pulmonary Arterial Hypertension (PAH) and Renal Dialysis.
Zdravilo Flolan je indicirano za zdravljenje pljučne arterijske hipertenzije (PAH) in za ledvično dializo.
Nineteen patients received 51 heparin dialyses and 19 received 44 epoprostenol dialyses in major controlled studies.
V glavnih nadzorovanih študijah je devetnajst bolnikov prejelo 51 dializ s heparinom, 19 bolnikov pa 44 dializ z epoprostenolom.
Over 12 weeks, a statistical difference (p<0.001) in the change from baseline for the 6MWT was observed in the group receiving epoprostenol and conventional therapy as compared to the group receiving conventional therapy alone (median: 63.5 vs. -36.0 meters; mean: 42.9 vs. -40.7 meters).
• Po več kot 12 tednih so pri skupini, ki je prejemala epoprostenol in konvencionalno zdravljenje, v primerjavi s skupino, ki je prejemala samo konvencionalno zdravljenje, opazili statistično razliko (p < 0,001) v spremembi od izhodišča za 6-minutni test hoje (mediana: 63,5 v primerjavi s -36,0 metri; sredina: 42,9 v primerjavi s -40,7 metri).
Editorial changes and clarifications were requested by the CHMP in the table of ADRs.
CHMP je zaprosil za redakcijske spremembe in pojasnila v preglednici neželenih dogodkov.
Except for five NYHA functional Class II patients, all patients were either functional Class III or Class IV.
funkcionalni razred po razvrstitvi NYHA (New York Heart Association), so bili vsi bolniki razvrščeni bodisi v III. ali IV. funkcionalni razred.
A statistically significant increase in cardiac index (CI), and statistically significant decreases in mean pulmonary arterial pressure (PAPm), mean right atrial pressure (RAPm), pulmonary vascular resistance (PVR), and mean systemic arterial pressure (SAPm) after 12 weeks of treatment were observed in patients who received epoprostenol chronically compared to those who did not.
Pri bolnikih, ki so kronično prejemali epoprostenol, so v primerjavi s tistimi, ki ga niso, opazili statistično značilno izboljšanje srčnega indeksa (SI) in statistično značilno zmanjšanje srednjega pljučnega arterijskega tlaka (PAPm), srednjega tlaka v desnem preddvoru (RAPm), pljučnega žilnega upora (PVR) in srednjega sistemskega arterijskega tlaka (SAPm) po 12 tednih zdravljenja.
Flolan is indicated for the treatment of pulmonary arterial hypertension (PAH) (idiopathic or heritable PAH and PAH associated with connective tissue diseases) in patients with WHO
Zdravilo Flolan je indicirano za zdravljenje pljučne arterijske hipertenzije (PAH) (idiopatske ali dedne PAH in PAH v povezavi z boleznimi vezivnega tkiva) pri bolnikih s simptomi funkcionalnega razreda III.-IV. po SZO za izboljšanje fizične zmogljivosti (glejte poglavje 5.1).
Patients were assigned to 1 of 4 bleeding risk groups prior to receiving their first study dialysis.
Preden so opravili svojo prvo dializo v okviru študije, so bili bolniki razvrščeni v 1 od 4 skupin s tveganjem za krvavitev.
Pulmonary Arterial Hypertension
„Zdravilo Flolan je indicirano za pljučno arterijsko hipertenzijo
Whereas
• Ob upoštevanju naslednjega:
It is available as:
Na voljo so naslednje jakosti:
Further information on NovoMix can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/novomix.
Nadaljnje informacije o zdravilu NovoMix so na voljo na spletni strani agencije: ema.europa.eu/medicines/human/EPAR/novomix.
The medicines are normally given shortly before a meal, but can be given just after a meal if necessary.
Zdravila se običajno dajejo malo pred obrokom, vendar se po potrebi lahko prejmejo tudi takoj po obroku.
What measures are being taken to ensure the safe and effective use of NovoMix?
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila NovoMix?
The European Medicines Agency decided that NovoMix's benefits are greater than its risks and it can be authorised for use in the EU.
Evropska agencija za zdravila je zaključila, da so koristi zdravila NovoMix večje od z njim povezanih tveganj in da se lahko odobri za uporabo v EU.
Other information about NovoMix
Druge informacije o zdravilu NovoMix
NovoMix received a marketing authorisation valid throughout the EU on 1 August 2000.
Za zdravilo NovoMix je bilo 1. avgusta 2000 izdano dovoljenje za promet, veljavno po vsej EU.
NovoMix is a replacement insulin.
Zdravilo NovoMix je nadomestni insulin.
Patients can inject themselves with NovoMix once they have been trained appropriately.
Bolniki si lahko zdravilo NovoMix vbrizgajo sami, če so bili za to ustrezno usposobljeni.
As for all medicines, data on the use of NovoMix are continuously monitored.
Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila NovoMix stalno spremljajo.
NovoMix 30 can be used in patients from 10 years of age.
Zdravilo NovoMix 30 se lahko uporablja pri bolnikih, starejših od 10 let.
For more information about using NovoMix, see the package leaflet or contact your doctor or pharmacist.
Za več informacij glede uporabe zdravila NovoMix glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
An overview of NovoMix and why it is authorised in the EU
Pregled zdravila NovoMix in zakaj je odobreno v EU
In type 2 diabetes, NovoMix can be given on its own or together with other diabetes medicines.
Pri sladkorni bolezni tipa 2 se zdravilo NovoMix lahko daje samostojno ali skupaj z drugimi zdravili za zdravljenje sladkorne bolezni.
Side effects reported with NovoMix are carefully evaluated and any necessary action taken to protect patients.
Neželeni učinki, o katerih so poročali pri zdravilu NovoMix, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
NovoMix 50 and NovoMix 70 can only be used in adults (from 18 years of age).
Zdravili NovoMix 50 in NovoMix 70 se lahko uporabljata le pri odraslih (starejših od 18 let).
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of NovoMix have been included in the summary of product characteristics and the package leaflet.
Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila NovoMix upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
What is NovoMix and what is it used for?
Kaj je zdravilo NovoMix in za kaj se uporablja?
What are the risks associated with NovoMix?
Kakšna tveganja so povezana z zdravilom NovoMix?
Why is NovoMix authorised in the EU?
Zakaj je bilo zdravilo NovoMix odobreno v EU?
By restoring the effects of insulin, the level of blood glucose is controlled better and the symptoms and complications of diabetes are reduced.
S ponovno vzpostavitvijo delovanja insulina je raven glukoze v krvi bolje uravnana, simptomi in zapleti sladkorne bolezni pa se zmanjšajo.
What benefits of NovoMix have been shown in studies?
Kakšne koristi je zdravilo NovoMix izkazalo v študijah?
Diabetes is a disease in which the body does not produce enough insulin or is not able to use insulin effectively, resulting in raised levels of glucose in the blood.
Sladkorna bolezen je bolezen, pri kateri telo ne proizvaja dovolj insulina ali ga ne more učinkovito izrabiti, zaradi česar je raven glukoze v krvi povišana.
In 5 studies involving a total of around 1,350 patients with type 2 diabetes, adding NovoMix medicines to other diabetes medicines (metformin, sulphonylureas, pioglitazone and liraglutide) also resulted in better control of blood glucose than the other medicines or NovoMix used alone.
V petih študijah, ki so vključevale skupaj približno 1 350 bolnikov s sladkorno boleznijo tipa 2, je dodajanje zdravila NovoMix drugim zdravilom za zdravljenje sladkorne bolezni (metforminu, sulfonilsečnini, pioglitazonu in liraglutidu) izboljšalo uravnanost ravni glukoze v krvi kot druga zdravila ali zdravilo NovoMix, uporabljeno samostojno.
The most common side effect with NovoMix (which may affect more than 1 in 10 people) is hypoglycaemia (low blood glucose levels).
Najpogostejši neželeni učinek zdravila NovoMix (ki se lahko pojavi pri več kot 1 od 10 bolnikov) je hipoglikemija (nizka raven glukoze v krvi).
NovoMix 30 gave almost identical results as biphasic human insulin 30 (a combination of 30% rapidacting and 70% intermediate-acting human insulin) in 294 adults with type 1 diabetes (when the pancreas cannot produce insulin) or type 2 diabetes (when the body is unable to use insulin effectively), and in 167 patients aged between 10 and 17 years with type 1 diabetes.
Z zdravilom NovoMix 30 so bili opaženi skoraj enaki rezultati kot z dvofaznim humanim insulinom 30 (kombinacija 30 % hitrodelujočega in 70 % srednjedolgodelujočega humanega insulina) pri 294 odraslih s sladkorno boleznijo tipa 1 (pri kateri trebušna slinavka ne more tvoriti insulina) ali sladkorno boleznijo tipa 2 (pri kateri telo ne more učinkovito izrabljati insulina) in pri 167 bolnikih, starih od 10 do 17 let, s sladkorno boleznijo tipa 1.
Several studies have found NovoMix to be effective either at reducing glycosylated haemoglobin (HbA1c, a substance which indicates how well blood glucose is controlled over 12 to 28 weeks) or in reducing blood glucose levels after a meal.
V več študijah je bilo ugotovljeno, da je zdravilo NovoMix učinkovito pri zmanjševanju glikoziliranega hemoglobina (HbA1c, tj. snovi, ki kaže, kako dobro je raven glukoze v krvi uravnana v obdobju od 12 do 28 tednov) ali pri zmanjševanju ravni glukoze v krvi po obroku.
The active substance in NovoMix, insulin aspart, is absorbed faster by the body than natural insulin and it starts working soon after it is injected.
Učinkovino v zdravilu NovoMix, insulin aspart, telo absorbira hitreje kot naravni insulin in začne delovati kmalu po injiciranju.
NovoMix is a range of insulin medicines used to treat patients who have diabetes and need insulin to keep their blood glucose (sugar) level controlled.
NovoMix je serija zdravil z insulinom, ki se uporabljajo za zdravljenje bolnikov, ki imajo sladkorno bolezen, in potrebujejo insulin za uravnavanje ravni glukoze (sladkorja) v krvi.
NovoMix medicines contain the active substance insulin aspart (100 units/ml) combined with protamine to make it longer acting.
Zdravila NovoMix vsebujejo učinkovino insulin aspart (100 enot/ml) v kombinaciji s protaminom, ki podaljša njegov učinek.
The medicines are given by injection under the skin of the abdomen (belly), thigh, upper arm or buttock.
Zdravila se dajejo z injiciranjem v podkožje trebuha, stegna, nadlakti ali zadnjice.
NovoMix medicines can only be obtained with a prescription and are available in cartridges and prefilled pens.
Predpisovanje in izdaja zdravil NovoMix je le na recept, na voljo pa so v vložkih in napolnjenih injekcijskih peresnikih.
For the full list of side effects and restrictions of NovoMix, see the package leaflet.
Za celoten seznam neželenih učinkov in omejitev pri uporabi zdravila NovoMix glejte navodilo za uporabo.
The dose of NovoMix depends on the patient's blood glucose levels, which should be tested regularly to find an effective dose.
Odmerek zdravila je odvisen od bolnikove ravni glukoze v krvi, ki jo je treba redno preverjati, da se določi najučinkovitejši odmerek.
NovoMix contains both insulin aspart and a longer-acting form called insulin aspart protamine, which is absorbed more slowly and works for longer.
Zdravilo NovoMix vsebuje insulin aspart in dolgodelujočo obliko, imenovano insulin aspart protamin, ki se absorbira počasneje in deluje dlje.
How does NovoMix work?
Kako zdravilo NovoMix deluje?
NovoMix acts in the same way as naturally produced insulin and helps glucose from the blood to enter cells.
Zdravilo NovoMix deluje enako kot naravno tvorjeni insulin in pomaga pri prehajanju glukoze iz krvi v celice.
How is NovoMix used?
Kako se zdravilo NovoMix uporablja?
NovoMix 50 and NovoMix 70 gave better overall control of blood glucose than biphasic human insulin 30 in 664 patients with type 1 or type 2 diabetes.
Zdravili NovoMix 50 in NovoMix 70 sta pri 664 bolnikih s sladkorno boleznijo tipa 1 ali tipa 2 omogočili na splošno boljše uravnanost ravni glukoze v krvi kot dvofazni humani insulin 30.
18 May 2011
18. maj 2011
The European Commission issued a decision on 18 May 2011.
Evropska komisija je odločbo izdala dne 18. maja 2011.
The company wanted the authorisation to be recognised in France and Spain (the ‘concerned Member States').
Družba je želela, da se dovoljenje za promet prizna tudi v Franciji in Španiji („zadevni državi članici“).
However, the Member States were not able to reach an agreement and the United Kingdom referred the matter to the CHMP for arbitration on 29 July 2010.
Vendar države članice niso mogle doseči soglasja in Združeno kraljestvo je dne 29. julija 2010 zadevo napotilo na CHMP v arbitražo.
What is Isotretinoin?
Kaj je zdravilo Isotretinoin?
Why was Isotretinoin reviewed?
Zakaj je bilo zdravilo Isotretinoin pregledano?
The marketing authorisation in the United Kingdom should also be suspended.
Dovoljenje za promet z zdravilom v Združenem kraljestvu je prav tako treba začasno umakniti.
Isotretinoin is a retinoid (a substance derived from vitamin A) that is used to treat severe acne that has not responded to standard treatments.
Zdravilo Isotretinoin je retinoid (snov, pridobljena iz vitamina A), ki se uporablja za zdravljenje hudih aken, ki se ne odzivajo na standardno zdravljenje.
Based on evaluation of the currently available data and the scientific discussion within the Committee, the CHMP concluded that bioequivalence of the generic isotretinoin capsules to the reference medicinal product has not been shown according to the current requirements.
Na podlagi ocene trenutno razpoložljivih podatkov in znanstvene razprave v odboru, je CHMP zaključil, da biološka enakovrednost generičnih kapsul izotretinoina z referenčnim zdravilom ni bila dokazana v skladu z veljavnimi zahtevami.
Isotretinoin capsules from Ranbaxy are a generic medicine based on a ‘reference medicine', Roaccutane, which has been marketed in the EU since 1984.
Kapsule zdravila Isotretinoin družbe Ranbaxy so generično zdravilo, zasnovano na podlagi „referenčnega zdravila“ Roaccutane, ki se v EU trži od leta 1984.
The CHMP therefore concluded that the benefits of the medicine do not outweigh its risks and recommended that the marketing authorisation should not be granted in the concerned Member States.
CHMP je tako zaključil, da koristi zdravila ne odtehtajo z njim povezanih tveganj in priporočil, da se dovoljenje za promet z zdravilom v zadevnih državah članicah ne odobri.
The European Medicines Agency has completed an arbitration procedure following a disagreement among Member States of the European Union (EU) regarding the authorisation of the generic isotretinoin-containing medicine from Ranbaxy (UK) Limited.
Evropska agencija za zdravila je končala postopek arbitraže, do katerega je prišlo po nesoglasju med državami članicami Evropske unije (EU) glede odobritve generičnega zdravila, ki vsebuje izotretinoin družbe Ranbaxy (UK) Limited.
The Agency's Committee for Medicinal Products for Human Use (CHMP) has concluded that the benefits of this medicine do not outweigh its risks, and the marketing authorisation granted in the United Kingdom cannot be recognised in other Member States of the EU: France and Spain.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da koristi tega zdravila ne odtehtajo z njim povezanih tveganj in da se dovoljenje za promet z zdravilom, ki je bilo odobreno V Združenem kraljestvu, ne sme priznati v drugih državah članicah Evropske unije: Franciji in Španiji.
The sebum accumulates under the skin and causes inflammation.
Sebum se nabira pod kožo in povzroča vnetje.
Acne is a skin disease caused by an excessive production of sebum (the skin's natural oil) from overactive sebaceous glands in the skin.
Akne so kožna bolezen, ki jo povzroča čezmerno nastajanje sebuma (naravno olje kože) zaradi prekomernega delovanja žlez lojnic v koži.
As the product information states that the capsules should be taken with food, Spain considered that a bioequivalence study under fed conditions would be required for the granting of the marketing authorisation.
Ker je v informacijah o zdravilu navedeno, da je treba kapsule jemati skupaj s hrano, je Španija menila, da je za odobritev dovoljenja za promet z zdravilom potrebna študija biološke enakovrednosti, ki bo izvedena pri neteščih preiskovancih.
In addition, the Committee recommended that the marketing authorisation for Isotretinoin Ranbaxy (UK) Limited in the United Kingdom be suspended until bioequivalence in the fed state is shown.
Odbor je tudi priporočil, da se dovoljenje za promet z zdravilom Isotretinoin Ranbaxy (UK) Limited v Združenem kraljestvu začasno umakne, dokler se ne dokaže biološka enakovrednost zdravila pri jemanju na poln želodec.
Isotretinoin works by decreasing the size and activity of the sebaceous glands in the skin, reducing sebum production and inflammation in the skin.
Zdravilo Isotretinoin deluje tako, da zmanjšuje velikost in delovanje žlez lojnic v koži ter s tem zmanjšuje nastajanje sebuma in vnetje kože.
The CHMP considered that demonstration of bioequivalence in the fed state was essential and in line with current guidance on investigation of bioequivalence.
CHMP je menil, da je dokazovanje biološke enakovrednosti zdravila pri jemanju na poln želodec ključnega pomena in v skladu z veljavno smernico o preučevanju biološke enakovrednosti.
However, the company was unable to demonstrate bioequivalence under fed conditions.
Vendar pa družba ni mogla dokazati biološke enakovrednosti zdravila pri jemanju na poln želodec.
The grounds for the referral were that the bioequivalence study to show that Ranbaxy's isotretinoin capsules produce the same levels of active substance in the body as Roaccutane had been performed under fasting conditions.
Podlaga za napotitev je bilo dejstvo, da je bila študija biološke enakovrednosti, s katero so želeli dokazati, da kapsule izotretinoina družbe Ranbaxy proizvajajo enake ravni zdravilne učinkovine v telesu kot zdravilo Roaccutane, izvedena pri teščih preiskovancih.
Ranbaxy (UK) Limited submitted the generic isotretinoin-containing medicine for mutual recognition on the basis of the initial authorisation granted by the United Kingdom (the ‘reference Member State') on 20 November 2006.
Družba Ranbaxy (UK) Limited je dne 20. novembra 2006 na podlagi prvotnega dovoljenja za promet z zdravilom, ki ga je odobrilo Združeno kraljestvo („referenčna država članica“), predložila vlogo za postopek z medsebojnim priznavanjem za generično zdravilo, ki vsebuje izotretinoin.
100 x 1 tablets (unit dose)
100 x 1 tableta (posamezni odmerek)
MA (EU) Number Invented name
(Izmišljeno) ime
Route of administration Packaging Package size
Velikost pakiranja
Invented name Strength Pharmaceutical Form
Številka EU Zaščiteno ime Jakost
EU/1/19/1357/001 KROMEYA 40 mg/0.8 ml
EU/1/19/1357/001 KROMEYA 40 mg/0,8 ml raztopina za injiciranje viala (steklo)
1 vial + 1 syringe + 1 needle + 1 adaptor + 2 alcohol pads
1 viala + 1 injekcijska brizga + 1 igla + 1 adapter + 2 alkoholna zloženca
Solution for injection vial (glass)
6 napolnjenih injekcijskih peresnikov + 6 alkoholnih zložencev
After 12 weeks, the viral load had fallen by more than 95%.
Po 12 tednih se je virusno breme zmanjšalo za več kot 95 %.
What measures are being taken to ensure the safe and effective use of Combivir?
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Combivir?
Other information about Combivir
Druge informacije o zdravilu Combivir
The full EPAR for Combivir can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Combivir je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The European Commission granted a marketing authorisation valid throughout the EU for Combivir on 18 March 1998.
Evropska komisija je dovoljenje za promet z zdravilom Combivir, veljavno po vsej Evropski uniji, izdala 18. marca 1998.
This is a summary of the European Public Assessment Report (EPAR) for Combivir.
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Combivir.
The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that Combivir's benefits are greater than its risks and recommended that it be given marketing authorisation.
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi zdravila Combivir večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
Because lamivudine and zidovudine have been available in the EU for a number of years, the company presented information from earlier studies of the two substances taken together.
Ker sta lamivudin in zidovudin v EU na voljo že vrsto let, je družba predložila podatke iz prejšnjih študij o jemanju teh dveh učinkovin skupaj.
CD4 cells (also called CD4 T cells) are white blood cells that are important for fighting infections, but they are killed by HIV.
Celice CD4 (imenovane tudi celice CD4 T) so bele krvne celice, ki so pomembne pri obrambi pred okužbami, vendar jih virus HIV uničuje.
In children (below 12 years of age) weighing between 14 and 30 kg, the dose depends on their weight.
Pri otrocih (mlajših od 12 let), ki tehtajo med 14 in 30 kg, je odmerek odvisen od njihove telesne mase.
The recommended dose of Combivir for patients over 12 years of age who weigh at least 30 kg is one tablet taken twice a day.
Priporočeni odmerek zdravila Combivir pri bolnikih, starejših od 12 let, ki tehtajo najmanj 30 kg, je ena tableta dvakrat na dan.
What are the risks associated with Combivir?
Kakšna tveganja so povezana z zdravilom Combivir?
What benefit of Combivir have been shown in studies?
Kakšne koristi je zdravilo Combivir izkazalo v študijah?
Combivir is available as tablets containing lamivudine 150 mg and zidovudine 300 mg.
Zdravilo Combivir je na voljo v obliki tablet, ki vsebujejo 150 mg lamivudina in 300 mg zidovudina.
It is not intended to provide practical advice on how to use Combivir.
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.